Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:12/5/2008

uld be scheduled no later than mid-December 2008, based on industry guidance published by the FDA. As a result, the end of January 2009 pre-NDA meeting date has affected the company's ability to meet its previous NDA submission target date. The company intends to seek the FDA's permission to complete the submission of the rolling NDA at the pre-NDA meeting. If the FDA grants such permission or accepts the NDA for filing after the submission is completed, no inference can be made concerning the FDA's ultimate decision on whether or not to approve the NDA. It is also possible that the FDA will advise the company at the pre-NDA meeting that the FDA will not allow the company to complete the submission of its NDA.

About ONCONASE(R)

ONCONASE is a first-in-class therapeutic product candidate based on Alfacell's proprietary ribonuclease (RNase) technology. A natural protein isolated from the leopard frog, ONCONASE has been shown in the laboratory and clinic to target cancer cells while sparing normal cells. ONCONASE triggers apoptosis, the natural death of cells, via multiple molecular mechanisms of action.

Alfacell has licensed the U.S. commercial rights for ONCONASE to Strativa Pharmaceuticals, a division of Par Pharmaceutical, Inc. Strategic marketing and distribution agreements for ONCONASE have been secured with Megapharm Ltd. for Israel, BL&H Co. Ltd. for Korea, Taiwan and Hong Kong, USP Pharma Spolka Z.O.O., an affiliate of US Pharmacia, for Eastern Europe, and GENESIS Pharma, S.A. for Southeastern Europe.

ONCONASE has been granted fast track status and orphan-drug designation for the treatment of malignant mesothelioma by the FDA. Additionally, ONCONASE has been granted orphan-drug designation in the European Union and Australia.

About Alfacell Corporation

Alfacell Corporation is the first company to advance a biopharmace
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
2. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
3. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
4. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... -- Fortune Oil and Gas, Inc. (OTCPink:FOGC), today announced that ... Inc. with the symbol (OTCPink : FOGCD). FINRA approved ... Also taking effect today is a ten for 1 ... event in the company,s progress according to CEO, ... proceed with the plan and still have any level ...
(Date:9/17/2014)... , Sept. 17, 2014  Soligenix, Inc. ... biopharmaceutical company developing products that address unmet medical ... biodefense, announced today that agreement has been reached ... on the design of a pivotal, Phase 3 ... for the treatment of cutaneous T-cell lymphoma (CTCL).  ...
(Date:9/16/2014)... , 17 settembre 2014 Hologic, Inc. ... il lancio in Europa del Tomcat, un nuovo ... una piattaforma multifunzionale completamente automatizzata, progettata per semplificare ... ed i rischi di errore legati alla gestione ... strumento Tomcat di Hologic riduce il carico di ...
Breaking Medicine Technology:Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 2Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 3Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 4Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 5Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 6Soligenix Announces FDA Clearance of Phase 3 Clinical Protocol of SGX301 in Cutaneous T-Cell Lymphoma 7Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 2Hologic annuncia il lancio dello strumento preanalitico Tomcat in Europa 3
... Reportlinker.com announces that a new market research report is ... http://www.reportlinker.com/p0484924/Epidemiology-Lupus.html In ... cases of systemic lupus erythematosus (SLE) in the seven ... women between 45 and 64 years of age. The ...
... NEW YORK, April 26, 2011 Reportlinker.com announces that ... catalogue: Epidemiology: Prostate Cancer ... period, prostate cancer incident cases will increase in all ... likely to be as a result of an aging ...
Cached Medicine Technology:Reportlinker Adds Epidemiology: Lupus 2Reportlinker Adds Epidemiology: Prostate Cancer 2
(Date:9/17/2014)... 17, 2014 The global metrology services ... due to the key driving factors of increasing demands ... CAGR of 8.2 % puts the metrology services market ... 2018, as stated in a Transparency Market Research report ... Share, Growth, Trends, and Forecast 2012 – 2018”. , ...
(Date:9/17/2014)... This news release is available in Spanish . ... overweight affect more than half of the population in ... organism, one of which affects liver function. Fat accumulates ... circumstances, causes inflammation, fibrosis and finally, cirrhosis. To date, ... been hepatic biopsy. Imaging techniques such as abdominal ecography ...
(Date:9/17/2014)... (GSA) invites all journalists to attend its ... interdisciplinary conference in the field of aging from ... may register free of charge. , An estimated 4,000 ... the Walter E. Washington Convention Center and Marriott Marquis ... From Cells to Societies" and the program schedule contains ...
(Date:9/17/2014)... September 17, 2014 Representatives with Capitol ... sponsor of Thursday’s Anti-Defamation League Event at the Four Seasons ... we consider it an honor to be a sponsor for ... Pain Institute. , Schocket went on to explain that the ... 600 community leaders and members at the Four Seasons to ...
(Date:9/17/2014)... Neon Sport and Fitmark have an ... industry’s most anticipated event, Joe Weider's Olympia Fitness & ... each take home a Neon Sport branded Fitmark Power ... gear. Fitmark will hold entries for the special prize ... , “There’s nothing more exciting than seeing our ...
Breaking Medicine News(10 mins):Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 2Health News:Metrology Services Market to Hit USD 720.3 Million by 2018: Transparency Market Research 3Health News:Magnetic resonance helps to detect and quantify fat in liver 2Health News:Join GSA in Washington, DC, for the Nation's Premier Aging Conference 2Health News:Capitol Pain Institute Sponsoring an Anti-Defamation League Event & Awards Dinner 2Health News:Electrifying Sports Nutrition Brand, Neon Sport, Pairs with Global Fitness Bag & Luggage Brand, Fitmark Bags, for an Exclusive Giveaway at Olympia Expo, This Weekend 2
... anti-HLA antibody assays both contribute to characterization ... ... immunosuppression, COLUMBIA, Md., June 1 Data developed by Cylex ... the American Transplantation Congress in Toronto, Canada, suggest,that cell-mediated immunity and ...
... also helped with severe fatigue among patients on chemotherapy ... the more common and unpleasant side effects of treatment ... by the ancient Chinese practice of acupuncture. , A ... and pain and shoulder dysfunction after neck dissection in ...
... treatment of choice for advanced, metastatic prostate cancer has ... testosterone the hormone that fuels prostate-cancer growth ... drugs. While such therapy buys time for patients, it ... resistant to the androgen deprivation and continues to grow. ...
... VA Three new studies published in the June ... focus on what role gender plays in the prognosis ... and the success rates of hearing aid implants in ... the wide variety of critical research being undertaken every ...
... pancreatic, kidney cancers, respectively , , SATURDAY, May ... cancer -- which historically carries a grim prognosis ... cancer drug Gemzar was used after surgery, new ... of pancreatic cancer patients are even candidates for ...
... death for female survivors; cardiovascular events for males ... survived Hodgkin lymphoma as children have an increased risk ... disease as adults, according to a new report. ... -- may help drive these increased risks, according to ...
Cached Medicine News:Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 2Health News:Cell-Mediated Immunity and Anti-HLA Antibody Tests Provide Insight to Immune Response in Renal Transplant Patients 3Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 2Health News:Acupuncture Eases Side Effects of Head, Neck Cancer Treatments 3Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 2Health News:How advanced prostate cancer becomes resistant to androgen-deprivation therapy 3Health News:New research offers insight into oral cancer, chronic pediatric ear infections, and hearing health 2Health News:New Hope for Tough-to-Treat Cancers 2Health News:New Hope for Tough-to-Treat Cancers 3Health News:Hodgkin Lymphoma Kids Face Greater Risk of Future Problems 2
... WardWatch has been designed specifically ... medical staff involved in ward rounds. ... medications and dosages, and consultations that ... (Specialist) or Registrar during Ward round ...
... is an advanced medical calculator ... Pediatric Dosing and Critical Care ... a logical complement to other ... the Daviss Drug Guide, PDR ...
... comprehensive guide provides safe, effective, ... information in a quickly accessible ... edition includes the latest drugs ... key nursing implications are highlighted ...
Provides immediate access to comprehensive coverage of more than 325 I.V. drugs, blood products, and solutions....
Medicine Products: